// added the section below on July 01 2024 // till here on July 01 2024

Cell Reprogramming Market

Cell Reprogramming Market by Type of Technology (Sendai Virus Reprogramming, mRNA Reprogramming, Episomal Reprogramming and Other Technologies), Type of Source Cell, Type of Application and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Pages
    293

  • View Count
    11922

Cell Reprogramming Market Overview

The cell reprogramming market is estimated to be worth $1.16 billion in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 8% during the forecast period. Over the years, advances in stem cell biology and regenerative medicine have enabled the discovery and development of a number of stem cell-based therapies. In fact, many believe that such interventions possess the potential to address several unmet needs related to the treatment of a wide range of diseases. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, effectively reversing the adverse physiological effects they cause. However, challenges, such as scarcity of healthy stem cell donors, adverse immunological reactions upon treatment (owing to donor-recipient haplotype mismatches), and a number of ethical concerns related to the use of stem cells, are impeding progress in this field. 

The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka’s team in 2006 revolutionized stem cell research. Through his Nobel prize winning research, Yamanaka was able to reprogram mature somatic cells into a stem-like (pluripotent) state. This finding not only established the means to synthesize stem cells (thereby, offering a virtually endless supply of research material), but also provided the means to alleviate the social stigma surrounding stem cell research. Presently, cellular reprogramming is perceived as a powerful and versatile tool, with numerous applications in fundamental research and medicine. It is worth mentioning that, today, many experts believe that stem cell therapies may be a possible solution to the COVID-19 pandemic. In fact, there are speculations, based on some evidence, that infected patients treated with stem cells may be more likely to successfully combat the symptoms of the disease. Research has also demonstrated that mesenchymal stem cells have the potential to be effectively used to treat SARS-CoV-2 induced pneumonia. Numerous partnerships have been inked amongst stakeholders in cell reprogramming market, indicative to future growth of the market. Interestingly, start-ups / university spin-offs have been the flagbearers in this upcoming field of therapeutics and are also expected to sustain the research momentum, over the coming years.

This image highlights the context of Cell Reprogramming Market report. The Nobel prize winning discovery of induced pluripotent stem cells (iPSCs) has resulted in great strides in stem cell research; cellular reprogramming is presently viewed as a powerful and versatile tool in both basic research and biomedical applications This image provides list of Cell Reprogramming (iPSC Generation) / Direct Reprogramming Service and Product Providers. Advances in cell reprogramming have paved way for a plethora of advanced therapeutic and research applications, resulting in lucrative business opportunities for industry and non-industry service provider firms This image presents current market landscape of Cell Reprogramming Service and Product Providers. Presently, majority of the service providers claim to offer iPSC generation services, using episomal reprogramming technologies, and are capable of working with various types of cells

Key Companies in Cell Reprogramming Market

Examples of key companies engaged in cell reprogramming market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Allele Biotechnology, ALSTEM, Applied Biological Materials, Axol Bioscience, Creative Bioarray, DefiniGEN, FUJIFILM Cellular Dynamics International, Lonza, Mogrify, REPROCELL, Stemnovate and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies providing cell reprogramming services and products, worldwide.

Recent Developments in Cell Reprogramming Market:

Several recent developments have taken place in the field of cell reprogramming market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In May 2023, Mekonos entered into a research agreement with bit.bio in order to integrate Mekonos' innovative ex vivo delivery system and bit.bio's distinctive opti-ox™ precision cellular reprogramming technology. Additionally, this collaboration aimed to expedite the cell engineering for research, drug discovery, and the advancement of cutting-edge cell therapies utilizing human cells.

Scope of the Report

The ‘Cell Reprogramming Market, 2020-2030’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the cell reprogramming market. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in cell reprogramming market.

This image highlights the geographical distribution of Cell Reprogramming (iPSC Generation) / Direct Reprogramming Service and Product Providers. Featuring the presence of several small and mid-sized firms, the cell reprogramming landscape is well-distributed across various regions; players have established multiple facilities to cater to the needs of their clients This image highlights competitive analysis of players engaged in the domain of Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services. Stakeholders are actively expanding their capabilities in order to enhance their respective cell reprogramming service portfolios and, thereby, maintain a competitive edge in this upcoming industry This image highlights the partnership activity undertaken by players engaged in Cell Reprogramming Market. The rising interest in this field is reflected in the number of partnerships, involving a varied range of cell types, inked in the recent past; the maximum partnering activity has been observed in the US

In addition to other elements, the market research report includes: 

  • A review of the overall landscape of cell reprogramming market, featuring a list of over 30 cell reprogramming (iPSC Generation) / direct reprogramming service and product providers and a detailed analysis of these providers based on a number of parameters, such as year of establishment, company size, geographical location, location of manufacturing facilities, type of  service (iPSC generation and direct reprogramming), type of offering (in-house development, kit, service, technology (for licensing) and iPSC lines), type of technology (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), type of vector used (viral vector, non-viral vector, mRNA and others), source cell for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), target indication(s), type of application (research and therapeutic) and additional service(s) offered (assay development, cell and tissue sourcing, cell banking, cell characterization, cell differentiation, cell sequencing, genome editing and other services).  
  • An insightful competitiveness analysis of iPSC generation and direct reprogramming service providers, based on supplier strength (based on a company’s employee count and years of experience) and service strength (which takes into account the number of reprogramming technologies offered, number of source cells used for iPSC generation used, number of target indications and number of manufacturing facilities).
  • Elaborate profiles of the industry players that offer cell reprogramming services and products. Each profiles features a brief overview of the company, its financial information (if available), details on cell reprogramming approaches, types of cell(s) utilized and differentiated, target indication(s), other drug discovery services offered, recent developments and an informed future outlook. 
  • A detailed analysis of more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, study design, current trial status, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials.
  • An analysis of the partnerships that have been established in cell reprogramming market since 2016, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • A list of stem cell therapy developers / manufacturers, generated based on a detailed analysis of a set of relevant parameters (such as company size (employee count), type of cell (s), indication count and existing partnership(s)), which are anticipated to partner with cell reprogramming service and product providers in the foreseen future.  

The key objective of cell reprogramming market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for cell reprogramming market during the forecast period. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the forecast period, 2020-2030. The market report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation  (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

This image provides information about completed, ongoing and planned clinical studies of stem cell therapies. In the last few years, over 540 clinical trials, evaluating various types of stem cell therapies have been initiated; this highlights the rising demand for iPSC generation and direct reprogramming strategies This image provides list of Potential Strategic Partners. An evaluation of more than 300+ stakeholders engaged in the development of stem cell therapies reveals several likely strategic partners for cell reprogramming service providers, across different geographical regions This image provides information on the current and future market trends and potential growth of Cell Reprogramming Service and Product Providers. The market is anticipated to grow at a CAGR of nearly 10% till 2030, and the opportunity is likely to be distributed across different types of technologies, applications and key geographical regions

The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Cristiana Pires (Co-Founder and Chief Executive Officer, Asgard Therapeutics)
  • Julien Maruotti (Chief Scientific Officer, Phenocell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is cell reprogramming?

Answer: Cell reprogramming is a novel and growing discipline encompassing the study of cellular identity modification.

Question 2: How big is the cell reprogramming market?

Answer: The cell reprogramming market size is estimated to be worth $1.16 billion in 2020.

Question 3: What is the projected market growth of the cell reprogramming market?

Answer: The cell reprogramming market is expected to grow at compounded annual growth rate (CAGR) of 8% during the forecast period 2020 – 2030.

Question 4: Who are the leading companies in the cell reprogramming market?

Answer: Examples of key companies engaged in cell reprogramming market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Allele Biotechnology, ALSTEM, Applied Biological Materials, Axol Bioscience, Creative Bioarray, DefiniGEN, FUJIFILM Cellular Dynamics International, Lonza, Mogrify, REPROCELL, Stemnovate and Thermo fisher Scientific.

Question 5: How many companies are currently engaged in the cell reprogramming market?

Answer: More than 65 companies are currently engaged in the cell reprogramming market, offering various cell reprogramming services and products.

Question 6: How many clinical trials investigating safety and efficacy of stem cell therapies have been registered till date?

Answer: Till date, more than 540 trials investigating safety and efficacy of stem cell therapies have been registered.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com